Should an artificial intelligence (AI) program that appears to have a better success rate than human pathologists be used to replace or augment humans in detecting cancer cells? We argue that some concerns-the "black-box" problem (ie, the unknowability of how output is derived from input) and automation bias (overreliance on clinical decision support systems)-are not significant from a patient's perspective but that expertise in AI is required to properly evaluate test results.
No takes yet. Share an insight, caveat, or question.
Anderson et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: